Compare OMH & BCTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | OMH | BCTX |
|---|---|---|
| Founded | 2015 | 2014 |
| Country | Singapore | Canada |
| Employees | N/A | N/A |
| Industry | Real Estate | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 32.6M | 28.8M |
| IPO Year | 2022 | 2025 |
| Metric | OMH | BCTX |
|---|---|---|
| Price | $1.24 | $3.97 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | N/A | ★ $40.00 |
| AVG Volume (30 Days) | 32.3K | ★ 176.8K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $28.40 | N/A |
| Revenue Next Year | $23.07 | $380.95 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.25 | $0.61 |
| 52 Week High | $4.33 | $14.68 |
| Indicator | OMH | BCTX |
|---|---|---|
| Relative Strength Index (RSI) | 44.13 | 41.58 |
| Support Level | $1.04 | $3.60 |
| Resistance Level | $1.37 | $4.42 |
| Average True Range (ATR) | 0.10 | 0.27 |
| MACD | -0.03 | 0.12 |
| Stochastic Oscillator | 11.43 | 56.06 |
Ohmyhome Ltd is a data and technology-driven property technology company based in Singapore. Through its subsidiaries, it operates a one-stop-shop property platform that provides end-to-end property solutions and services for its customers, which comprises brokerage services and emerging and other services, such as home renovation and furnishing services, listing and research, mortgage referral, legal services, and insurance referral services. The company derives its revenues from two sources: revenue from brokerage services, property management services, and revenue from emerging and other services.
BriaCell Therapeutics Corp is a clinical-stage biotechnology company focused on developing immunotherapies for cancer treatment, particularly breast cancer. The company's targeted immunotherapy program, Bria-IMT, is a targeted cell-based immunotherapy in end-stage clinical trials aiming to improve outcomes for patients with breast cancer. BriaCell also develops Bria-OTS, personalized off-the-shelf immunotherapies for breast and prostate cancer. BriaCell is involved in clinical collaborations to explore combination therapies for enhanced cancer treatment options.